41 results about "Spinal Nerve Disorders" patented technology

The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.

Disclosed are methods for quantification of a perivascular space in a subject's central nervous system. The methods include administering contrast agent into cerebrospinal fluid of the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in the perivascular space within the region of interest.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

This invention discloses an essential oil-based intervention system for the simultaneous treatment of heart and brain function based on dual feedback of eye movement and heart rate variability, belonging to the field of rehabilitation medicine technology. The system includes: a data synchronization acquisition module, which acquires heart rate variability data and eye movement characteristic data and generates a synchronized physiological data stream; a dual feedback joint assessment module, which assesses the patient's real-time physical and mental state level based on the synchronized physiological data stream; a synchronized intervention decision module, which generates essential oil atomization control instructions and eye movement training control instructions in parallel according to the physical and mental state level; and a synchronized intervention execution module, which drives the essential oil atomization unit and the eye movement training unit to execute corresponding intervention actions synchronously at the hardware level on the time axis. This invention achieves integrated and precise intervention of heart and brain function through dual-modal physiological feedback closed loop and synchronized control, effectively solving the problems of brain separation, delayed intervention, and poor coordination in traditional rehabilitation centers, and improving the synchronous rehabilitation effect of cognitive function and autonomic nervous function in stroke patients.

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

Methods of treatment and treatment systems for performing radiomodulatory stereotactic radiosurgery to treat brain disorders in which target neural tissues associated with the brain disorder are sensitized to radiation by administration of a molecular substance and / or non-targeted critical structures are protected from radiation by a molecular substance, in order to treat disorders of brain circuitry. Specific embodiments disclose means for treating pain, obesity and drug addiction.

The application relates to the technical field of brain detection, and particularly discloses a test auxiliary system and method for brain diseases, wherein the system comprises an automatic control module, a light source control module and a data synchronization module. The automatic control module is used for inputting an open-closed eye test rule, converting the open-closed eye test rule into a light period control rule, and generating an open or off light instruction according to the light period control rule. The light source control module is used for controlling the switch state of an access light source according to the open or off light instruction, so as to simulate an open eye state and a closed eye state. The data synchronization module is used for acquiring environment brightness data and light source switch state data, and is also used for acquiring an electroencephalogram from an electroencephalogram test device and generating a visual report of the open-closed eye test. The technical scheme of the application can effectively solve the problem that a patient with a brain problem found in a nuclear magnetic resonance examination does not cooperate in an open-closed eye test, and improve test accuracy.

The present disclosure provides an AI-based clinical decision support system comprising an input module configured to receive clinical information comprising brain scan data, an analysis module configured to parse the clinical information using statistical measures from functional connectivity analysis with counterfactual explanations to identify brain connectivity patterns associated with brain disorders, and an output module configured to present a recommended diagnosis and explanation comprising attribution information identifying connectivity features contributing to the diagnosis. The brain scan data comprises functional magnetic resonance imaging, electroencephalography, and magnetoencephalography data. The statistical measures comprise functional connectivity analysis and graph theory metrics including degree metrics, betweenness centrality measures, and clustering coefficients. The analysis module comprises a functional connectivity engine configured to process brain scan data and generate connectivity features, a feature bank configured to store connectivity features, and modeling backbones configured to analyze connectivity features using machine learning techniques.

The present disclosure describes methods comprising administering N-acetylcysteine (NAC) or a pharmaceutically-acceptable salt or congener thereof. The disclosed methods can be used to treat a brain disorder.

The present disclosure provides a method of EEG-based biomarker discovery and commercialization for personalized diagnosis and treatment of brain disorders. Further, the method may include receiving, using a communication device, a brain-wave data from a diagnostic device. Further, the brain-wave data corresponds to a graphical representation of an electrical activity of a brain of an individual. Further, the individual may be receiving at least one therapeutic for at least one brain disorder. Further, the method may include analyzing, using a processing device, the brain-wave data based on an artificial intelligence (AI) model. Further, the method may include generating, using the processing device, at least one output data based on the analyzing. Further, the method may include transmitting, using the communication device, the at least one output data to at least one device.

The invention discloses a speech decoding analysis method and system based on electroencephalogram signals and computer equipment, and belongs to the technical field of electroencephalogram signal processing.The speech decoding analysis method comprises the following steps that a corpus is selected as natural stimulation, and the corpus is continuous natural language streaming media; acquiring a multi-channel EEG (electroencephalogram) signal of the subject under natural stimulation; dividing the multi-channel EEG signals into short-time EEG signals corresponding to single words in a corpus based on timestamps; the short-time EEG signals are converted into frequency domain power spectral density, and the power ratio of the short-time EEG signals is calculated based on the power spectral density; words in the corpus are classified based on the power ratio, and language decoding is achieved. According to the method, the power ratio is used as a biomarker, fine decoding of different word classes of words under natural stimulation by short-time EEG signal frequency domain features is realized, and a new perspective is provided for revealing a potential neural mechanism of a brain disorder patient.

The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for increasing neural plasticity of the neuronal cell, and a method of using thereof for treating a brain disorder.

An ultrasound neuromodulation system and method, e.g. for treating brain disorders, directs ultrasound transducers to sequentially energise plural candidate target volumes. Physiological responses to

Targeted and individualized methods are provided herein for determining specific treatment sites based on an individual patient. Embodiments described herein may use functional and / or structural connections to create brain mapping of the patient and / or control groups having the same metrics as the patient, and combinations thereof in determining target locations for stimulation treatment.

The present invention provides R-3,4-methylenedioxy-N,N-dimethylamphetamine, and salts thereof, for treating brain disorders.

The present invention refers to the biomedical field. Particularly, the present invention refers to an in vitro method for obtaining a cortical brain organoid, a cortical brain organoid obtained or obtainable by said method and its application as a medicament, preferably in a method of treating a brain disorder, condition, or disease.

Disclosed is a pharmaceutical composition for preventing or treating a brain disease, containing as an active ingredient an ErbB3-binding protein 1 (EBP1) protein or a polynucleotide sequence encoding the EBP1 protein, wherein an EBP1 N84A / N204A protein, which is an EBP1 mutant in an asparagine endopeptidase (AEP)-uncleavable form, and a polynucleotide encoding the same can reduce amyloid beta production and enhance cognitive function in the early stages of Alzheimer's disease, and thus the composition can be advantageously used as a therapeutic agent for brain diseases including sporadic Alzheimer's disease.

A computer-implemented method for brain mapping and target identification for interventional planning using magnetic resonance imaging (MRI) includes receiving, by a computing system that includes at least one processor in communication with at least one memory system and that is in communication to receive data acquired using an MRI system, MR data from the MRI system. The method further includes analyzing the received MR data to monitor and identify motion in real-time, determining a set of useable MR data from the acquired MR data based on the identified motion, generating a map of the subject's brain based on the set of useable MR data and identifying a target location in the subcallosal cingulate (SCC) region of the subject's brain based on the map of the subject's brain. The target location can be a point of convergence of multiple fiber bundles passing through the SCC region. The method can further include generating a report indicating the target location.

The present invention provides an antibody that specifically binds to GPR158 and inhibits the GAP activity of GPR158 by RGS7 / G [beta] 5. The antibodies are useful in the diagnosis and treatment of mood disorders, mood disorders, and brain conditions.

Provided herein are ibogaine compounds which can be useful for methods of treating a neuropsychiatric disease or neurological disorder, for increasing neural plasticity, or for modulating the function of a serotonin transporter.

The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.

Provided herein are tetracyclic heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.

Provided herein are tetracyclic heterocyclic compounds useful in methods of treating a disease or for increasing neural plasticity. These compounds can also be used to increase dendritic spine density.

Methods of treatment and treatment systems for performing radiomodulatory stereotactic radiosurgery to treat brain disorders in which target neural tissues associated with the brain disorder are sensitized to radiation by administration of a molecular substance and / or non-targeted critical structures are protected from radiation by a molecular substance, in order to treat disorders of brain circuitry. Specific embodiments disclose means for treating pain, obesity and drug addiction.

Aspects of the invention are directed to methods of stimulating or promoting neurogenesis by administering to a subject of a composition comprising a cyclodextrin and a polyethylene glycol to alleviate learning, memory and cognitive deficits present in subjects afflicted with various brain disorders or from neurodegenerative disorder associated with aging.